EN DE
Watch Ikapharmindo Putramas Tbk. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ikapharmindo Putramas Tbk. (IKPM) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Ikapharmindo Putramas Tbk. stock IDR 182, price IDR 133, upside +36.7%, quality 46 out of 100. Rating: undervalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID · ISIN ID1000199409

IP Ikapharmindo Putramas Tbk. logo Thin data Nov 4, 2026

Ikapharmindo Putramas Tbk.

IKPM · JK
Speculative

The stock costs 27% less than our calculation considers fair.

Fair value 181.76 IDR · Undervalued
Low debt
Revenue last quarter +27% vs. a year ago.
Quality 46/100
Mixed vs. peers (4/10)
Weak Growth (revenue 3y −3.0 %/yr in IDR)
Loss-making · -4.2% net margin (TTM)
Narrow moat 18/100 · thin data
Thin data
⚠ Small free float
Watch Ikapharmindo Putramas Tbk. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

324.76 IDR 129.00 IDR Fair Value 181.76 IDR Nov 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

36‑month range 129.00 IDR – 324.76 IDR · fair‑value band 146.87 IDR – 242.03 IDR · the 133.00 IDR price screens below the 181.76 IDR fair value. As of Nov 4, 2026.

Follow Ikapharmindo Putramas Tbk. in your weekly email

Every Wednesday you see whether Ikapharmindo Putramas Tbk. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Ikapharmindo Putramas Tbk engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. It operates through three segments: Non Pharma, Pharma, and Contract Manufacturing.

Show moreShow less

The company offers prescription medicines in various areas, including neurology, psychiatry, dermatology, nephrology, gastroenterology, and nutraceuticals; and pharmaceuticals, vitamins, and over-the-counter products. It also provides hair and baby care products.

PT Ikapharmindo Putramas Tbk was founded in 1978 and is headquartered in Jakarta Timur, Indonesia. PT Ikapharmindo Putramas Tbk is a subsidiary of PT Ikapharma Inti Mas.

Stock analysis

Ikapharmindo Putramas Tbk. (IKPM) currently trades at 133.00 IDR, while our model-based Fair Value estimate is 181.76 IDR, implying the stock looks roughly 27% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 201.43 IDR per share, and 6 of the 7 models we run sit above the 133.00 IDR price.

Bear case: the Asset-Based group reads lowest at 33.45 IDR, and 1 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: 146.87 IDR (bear) to 242.03 IDR (bull), the price of 133.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Ikapharmindo Putramas Tbk. reported revenue of 364B IDR in FY2025 versus 399B IDR in FY2022, a compound −3.0%/yr. Reported net income was −28.8B IDR in FY2025.

Key figures

Market cap 224B IDR (≈ $12.4M) Micro · P/S ratio 0.56 · Net margin −4.2% · Return on equity −7.3% · Return on assets (EBIT) 3.6% (4-year average) · Operating margin 3.0% · Revenue (TTM) 400B IDR · Revenue growth (YoY) +27.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 37%, IKPM screens cheaper than that median.

Fair Value models

Bear 146.87 IDR Fair Value 181.76 IDR Bull 242.03 IDR
Price 133.00 IDR · Upside +36.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 142.86 IDR 179.53 IDR 242.03 IDR 78
Growth DCF 146.87 IDR 181.76 IDR 236.66 IDR 76
5Y Revenue Exit 140.88 IDR 190.75 IDR 263.17 IDR 70
All 7 models by family
DCF Models
FCF DCF 142.86 IDR 179.53 IDR 242.03 IDR 78
5Y Revenue Exit 140.88 IDR 190.75 IDR 263.17 IDR 70
10Y Revenue Exit 138.20 IDR 173.37 IDR 210.81 IDR 65
Multiples
EV/Revenue 149.38 IDR 201.43 IDR 253.49 IDR 54
Asset-Based
NCAV (Graham) 22.08 IDR 33.45 IDR 41.81 IDR 54
Growth DCF
Growth DCF 146.87 IDR 181.76 IDR 236.66 IDR 76
Rev-Margin DCF 140.88 IDR 193.71 IDR 258.64 IDR 70

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 8
Are margins and returns getting better?
Cashflow 55
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 77
Does it invest with discipline instead of growing at any price?
Low Volatility 54
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.6% (2022) → −6.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch IKPM, get fair value alerts →

Compare Ikapharmindo Putramas Tbk. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Bottom 25%
Fair Value upside +36.7% · Above median
Profitability
Return on assets −6.2% · Bottom 25%
Net margin (12 months) −4.2% · Bottom 25%
Operating margin (12 months) 3.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 27.2% · Top 25%

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/B 1.02× · Cheapest 25%
P/S (12 months) 0.56× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)82 · sector 68
FUTURE (revenue growth)100 · sector 21
PAST (return on equity)0 · sector 32
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 58

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
JD Health International Inc 6618 HK$43.26 HK$75.61 +75% vs IKPM
Luyan Pharma Co 002788 ¥9.53 ¥15.91 +67% vs IKPM
Yifeng Pharmacy Chain Co 603939 ¥27.07 ¥40.59 +50% vs IKPM
Yixintang Pharmaceutical Group 002727 ¥13.48 ¥18.92 +40% vs IKPM
DaShenLin Pharmaceutical Group 603233 ¥21.49 ¥25.52 +19% vs IKPM
MedPlus Health Services Limited MEDPLUS ₹604.60 ₹707.67 +17% vs IKPM
Anhui Huaren Health Pharmaceutical Co 301408 ¥13.81 ¥15.40 +12% vs IKPM
LBX Pharmacy Chain Joint Stock Company 603883 ¥14.97 ¥16.43 +10% vs IKPM
ShuYu Civilian Pharmacy Corp 301017 ¥14.34 ¥5.91 −59% vs IKPM
Apotea AB APOTEA kr 104.30 kr 39.50 −62% vs IKPM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ikapharmindo Putramas Tbk.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ikapharmindo Putramas Tbk. Fair Value". https://www.fairvalue-calculator.com/stock/IKPM

Frequently asked questions

Is Ikapharmindo Putramas Tbk. (IKPM) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 181.76 IDR versus a price of 133.00 IDR, about +37% upside (undervalued).
What is the fair value of IKPM?
Our model-based fair value for Ikapharmindo Putramas Tbk. is 181.76 IDR (as of Nov 4, 2026), built from audited fundamentals. The current price: 133.00 IDR.
What is the quality score of IKPM?
Ikapharmindo Putramas Tbk. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ikapharmindo Putramas Tbk. (IKPM)?
Our model-based price target is the fair value of 181.76 IDR (as of Nov 4, 2026) from 7 valuation models. Cautious scenario 146.87 IDR, optimistic scenario 242.03 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Ikapharmindo Putramas Tbk. stock forecast for 2026?
Our models put fair value at 181.76 IDR, about +37% upside versus a price of 133.00 IDR (undervalued). Cautious scenario 146.87 IDR, optimistic scenario 242.03 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Ikapharmindo Putramas Tbk. (IKPM)?
Ikapharmindo Putramas Tbk. reported trailing-twelve-month revenue of about 400B IDR (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Ikapharmindo Putramas Tbk. (IKPM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ikapharmindo Putramas Tbk. it is 181.76 IDR per share (as of Nov 4, 2026), against a price of 133.00 IDR. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Ikapharmindo Putramas Tbk. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, IKPM trades below its calculated fair value: price 133.00 IDR, fair value 181.76 IDR, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IKPM?
No. The price is what the market pays today (133.00 IDR); the fair value is what the company's own numbers justify (181.76 IDR). For Ikapharmindo Putramas Tbk. the two are 48.76 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Ikapharmindo Putramas Tbk. worth?
The market values Ikapharmindo Putramas Tbk. at about 224B IDR (market capitalisation, as of Nov 4, 2026). Per share that is 133.00 IDR; our models calculate a fair value of 181.76 IDR per share.
What do the bullish and bearish scenarios say about IKPM?
Our models span a range for Ikapharmindo Putramas Tbk.: cautious scenario 146.87 IDR, base 181.76 IDR, optimistic 242.03 IDR per share (as of Nov 4, 2026, price 133.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ikapharmindo Putramas Tbk. (IKPM)?
Balance-sheet figures for Ikapharmindo Putramas Tbk. (as of Nov 4, 2026): return on equity −7.3%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is IKPM from its 52-week high?
Ikapharmindo Putramas Tbk. trades at 133.00 IDR, about 53% below its 52-week high of 282.00 IDR and 3% above the low of 129.00 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 181.76 IDR is for.
Which stocks are comparable to Ikapharmindo Putramas Tbk.?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ikapharmindo Putramas Tbk. stock attractive at the current price?
The data as of Nov 4, 2026: price 133.00 IDR, calculated fair value 181.76 IDR (+37%), Quality Score 46/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IKPM calculated?
We run Ikapharmindo Putramas Tbk. through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 181.76 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ikapharmindo Putramas Tbk. currently trades 27% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ikapharmindo Putramas Tbk. (IKPM)?
The closing price on Nov 6, 2026 was 133.00 IDR. Our model-based fair value is 181.76 IDR, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ikapharmindo Putramas Tbk. right now?
The large discount to fair value meets weak quality (46/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (146.87 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Ikapharmindo Putramas Tbk.

How large is the market capitalisation of Ikapharmindo Putramas Tbk. (IKPM)?
The market capitalisation of Ikapharmindo Putramas Tbk. is 224B IDR (≈ $12.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ikapharmindo Putramas Tbk. (IKPM)?
The price-to-sales ratio of Ikapharmindo Putramas Tbk. is 0.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Ikapharmindo Putramas Tbk. (IKPM)?
The net margin of Ikapharmindo Putramas Tbk. is −4.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ikapharmindo Putramas Tbk. (IKPM)?
The return on equity (ROE) of Ikapharmindo Putramas Tbk. is −7.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ikapharmindo Putramas Tbk. (IKPM)?
On an EBIT basis the return on assets of Ikapharmindo Putramas Tbk. is 3.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ikapharmindo Putramas Tbk. (IKPM)?
The operating margin of Ikapharmindo Putramas Tbk. is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ikapharmindo Putramas Tbk. (IKPM)?
Revenue at Ikapharmindo Putramas Tbk. is growing +27.2% versus a year earlier (3y avg −3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ikapharmindo Putramas Tbk. (IKPM)?
Earnings per share at Ikapharmindo Putramas Tbk. are growing −24.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Ikapharmindo Putramas Tbk. in the live analysis

One click puts Ikapharmindo Putramas Tbk. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.